A humanized anti-tumor necrosis factor-alpha monoclonal antibody that acts as a partial, competitive antagonist of the template antibody.

We have constructed several humanized versions of a monoclonal antibody (MAb78) against human tumor necrosis factor-alpha (huTNF-alpha) retaining the complementarity-determining regions (CDR) of the original mouse MAb with or without a variable number of original framework region (FR) residues. All versions, except one, showed a loss of binding affinity and neutralizing potency of at least 10-fold compared to the original mouse MAb or its chimeric equivalent. In some cases, however, the decrease in neutralizing potency was significantly greater than the decrease in binding affinity. Two humanized versions showing the greatest dissociation between these two parameters were studied for their capacity to inhibit the neutralizing activity of chimeric or murine MAb78 when used at concentrations that bound but only partially neutralized huTNF-alpha. One humanized version (MAb78D) was indeed able to do so, whereas the other (MAb78C) was not found to exert any inhibitory activity at all concentrations tested. The antagonistic effect of MAb78D was concentration dependent and could be overcome by increasing the concentrations of chimeric or murine MAb78. Two different models of MAb78-huTNF-alpha interaction that may help explain the antagonist activity of humanized MAb78D are discussed.

Mode of interaction between tumor necrosis factor alpha and a monoclonal antibody expressing a recurrent idiotype.

Tumor Necrosis Factor alpha (TNF alpha) is an inflammatory cytokine which exists mainly as a 51kD complex built up of 3 identical, noncovalently-linked polypeptide subunits. We have raised monoclonal antibodies (mAb) against human TNF alpha (huTNF alpha). One of these mAb (mAb78, mouse IgG1k) was studied in detail. mAb78 expresses a recurrent idiotype typical of the BALB/c anti-huTNF alpha antibody response. HuTNF alpha bound to mAb78 with an affinity constant (Kobs) of 3.2 x 10(10)M-1. The number of huTNF alpha-binding sites per mAb78 molecule was approximately 0.7. At concentrations higher than the Kobs mAb78 neutralized huTNF alpha at a approximately 1.3:1 molar ratio. mAb78 precipitated huTNF alpha in a double immunodiffusion assay in agar. Gel-filtration experiments of mAb78-huTNF alpha mixtures, that had been set up in large antigen excess, detected complexes of 570 kD as the smallest ones formed under these conditions. We propose that these results are accommodated best by a model according to which cyclic complexes built up of 3 mAb78 and 2 huTNF alpha molecules are the smallest units formed upon interaction of the reagents. In view of this model we discuss how huTNF alpha and mAb78 can undergo a precipitin reaction.